Succinate Receptor 1

琥珀酸受体(SUCNR1,也称为 GPR91)是一种 G 蛋白偶联受体,与 P2Y 嘌呤受体家族密切相关。琥珀酸受体被确定为由生理水平的克雷布斯循环中间体琥珀酸和其他二羧酸(如马来酸)激活。它在多种组织中表达,包括血细胞、脂肪组织、肝脏、视网膜和肾脏。在这些组织中,这种受体及其配体琥珀酸最近成为局部应激情况下的新介质,包括缺血、缺氧、毒性和高血糖。除其他外,琥珀酸受体参与将免疫细胞募集到移植组织。此外,它被证明在糖尿病视网膜病变的发展中起着关键作用。然而,最突出的是,肾脏局部增加的琥珀酸水平和琥珀酸受体活化,刺激全身和局部肾素-血管紧张素系统的作用开始显现:琥珀酸受体是高血压发展和糖尿病和代谢综合征中可能的纤维化的关键介质。

The succinate receptor (SUCNR1, also known as GPR91) is a G protein-coupled receptor that is closely related to the family of P2Y purinoreceptors. The Succinate receptor was identified as being activated by physiological levels of the Kreb's cycle intermediate succinate and other dicarboxylic acids such as maleate. It is expressed in a variety of tissues, including blood cells, adipose tissue, the liver, retina, and kidney. In these tissues, this receptor and its ligand succinate have recently emerged as novel mediators in local stress situations, including ischemia, hypoxia, toxicity, and hyperglycemia. Amongst others, the succinate receptor is involved in recruitment of immune cells to transplanted tissues. Moreover, it was shown to play a key role in the development of diabetic retinopathy. However, most prominently, the role of locally increased succinate levels and succinate receptor activation in the kidney, stimulating the systemic and local renin–angiotensin system, starts to unfold: the succinate receptor is a key mediator in the development of hypertension and possibly fibrosis in diabetes mellitus and metabolic syndrome.

共 4种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
4'-O-Methylbavachalcone
4'-O-甲基补骨脂查尔酮

4'-O-Methylbavachalcone 是一种具有口服活性的异戊烯基黄酮类成分,可通过 IC50 为 10.1 μM、Ki 为 4.6 μM 抑制 SARS-CoV papain-like protease (PLpro) 活性,并可抑制聚 (ADP-核糖) 聚合酶介导的细胞死亡 (parthanatos)、减小脑梗死体积、结合 SUCNR1 的正构位点、阻断琥珀酸与 SUCNR1 的相互作用、抑制 SUCNR1 活性、阻断 NFATc4 的核转位、抑制 ERK1/2 信号通路的激活、抑制心肌细胞肥大并恢复 α-辅肌动蛋白 (α-actinin) 的表达,因此可用于缺血性脑卒中、SARS-CoV 及心肌细胞肥大的相关研究。

20784-60-5
Inhibitor
99.64%
4'-O-甲基补骨脂查尔酮
SUCNR1 antagonist-1

SUCNR1 antagonist-1 是一种口服有效的 SUCNR1 拮抗剂,可与关键残基 Glu221.31 形成稳定的水桥氢键以稳定结合构象并调节蛋白构象灵活性,从而阻断琥珀酸介导的 SUCNR1 信号通路、诱导细胞凋亡 (apoptosis),可用于结直肠癌的研究。

Inhibitor
SUCNR1 antagonist-1
SUCNR1-IN-1

SUCNR1-IN-1 是一种具有口服活性的 SUCNR1 抑制剂,在 100 μM 时对大鼠和小鼠 SUCNR1 的抑制率分别为 23% 和 56%,可用于类风湿关节炎的研究。

2711753-52-3
Inhibitor
99.39%
SUCNR1-IN-1
SUCNR1-IN-2

SUCNR1-IN-2(Statement 35)是一种 SUCNR1 抑制剂,可用于神经退行性疾病(如神经炎症)的研究。

2988733-54-4
Inhibitor
99.74%
SUCNR1-IN-2

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础